{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:26:47Z","timestamp":1794432407234,"version":"4.9.1"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background\/Purpose:<\/jats:title>\n                    <jats:p>To assess the effects of faricimab versus aflibercept on epiretinal membrane (ERM) formation in eyes with diabetic macular edema.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Post hoc analysis of phase 3 YOSEMITE\/RHINE trial data in eyes with diabetic macular edema receiving faricimab every 8 weeks (Q8W), faricimab treat-and-extend (T&amp;E; up to Q16W depending on central subfield thickness and best-corrected visual acuity), or aflibercept Q8W for 100 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      ERMs developed in 3.8% (23\/602) of eyes treated with faricimab Q8W, 5.1% (31\/608) with faricimab T&amp;E, and 7.6% (45\/590) with aflibercept Q8W at 100 weeks. ERMs were less likely with faricimab Q8W versus aflibercept Q8W (odds ratio [OR] 0.48, 95% confidence interval [CI] 0.29\u20130.81,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0055). The mean (SD) best-corrected visual acuity at 100 weeks in eyes with and without ERMs were 69.2 (13.6) letters [20\/40 Snellen] versus 73.8 (13.1) [20\/40 Snellen], respectively; the mean (SD) CSTs were 315.8 (99.2) versus 274.6 (74.1)\n                      <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>\n                      m. Faricimab T&amp;E dosing intervals were extended \u2265 Q12W in 79.7% of eyes without ERMs versus 50.0% with ERMs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Risk of ERMs was 52% lower with faricimab Q8W versus aflibercept Q8W over 100 weeks in eyes with diabetic macular edema, suggesting a potential role for faricimab in reducing pre-retinal fibrotic proliferation. The results may help inform physician\/patient decision-making when initiating intravitreal therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration:<\/jats:title>\n                    <jats:p>NCT03622580 and NCT03622593.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004572","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T17:00:09Z","timestamp":1752685209000},"page":"2003-2011","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["IMPACT OF FARICIMAB VERSUS AFLIBERCEPT ON EPIRETINAL MEMBRANE FORMATION OVER 2 YEARS IN PATIENTS WITH DIABETIC MACULAR EDEMA IN THE PHASE 3 YOSEMITE AND RHINE TRIALS"],"prefix":"10.1097","volume":"45","author":[{"given":"Glenn J.","family":"Jaffe","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Duke University, Durham, North Carolina;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"De\u00e1k","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Gibson","sequence":"additional","affiliation":[{"name":"Roche Products Ltd., Welwyn Garden City, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul N.","family":"Khurana","sequence":"additional","affiliation":[{"name":"Northern California Retina Vitreous Associates, Mountain View, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Nudleman","sequence":"additional","affiliation":[{"name":"Shiley Eye Institute at UC San Diego Health, La Jolla, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Ogura","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Schmidt-Erfurth","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey","family":"Wang","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd., Mississauga, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter D.","family":"Westenskow","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd., Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Vision Sciences, Unity Health Toronto \u2013 St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Yiu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Vision Science, University of California, Davis Health, Sacramento, California; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Willis","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20251021","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/bjophthalmol-2014-305966","article-title":"Prevalence of vitreomacular interface abnormalities on spectral domain optical coherence tomography of patients undergoing macular photocoagulation for centre involving diabetic macular oedema","volume":"99","author":"Akbar Khan","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"R2-20251021","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s41598-020-57509-6","article-title":"Incidence and treatment outcomes of secondary epiretinal membrane following intravitreal injection for diabetic macular edema","volume":"10","author":"Kang","year":"2020","journal-title":"Sci Rep"},{"key":"R3-20251021","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1097\/IAE.0000000000000349","article-title":"Idiopathic epiretinal membrane","volume":"34","author":"Bu","year":"2014","journal-title":"Retina"},{"key":"R4-20251021","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1097\/IAE.0000000000002569","article-title":"En face image-based analysis of retinal traction caused by epiretinal membrane and its relationship with visual functions","volume":"40","author":"Hirano","year":"2020","journal-title":"Retina"},{"key":"R5-20251021","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/ceo.13914","article-title":"Epiretinal membrane: a review","volume":"49","author":"Fung","year":"2021","journal-title":"Clin Exp Ophthalmol"},{"key":"R6-20251021","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1167\/iovs.02-0276","article-title":"Potential role of the angiopoietin\/tie2 system in ischemia-induced retinal neovascularization","volume":"44","author":"Takagi","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R7-20251021","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nrd.2016.278","article-title":"Therapeutic targeting of the angiopoietin-TIE pathway","volume":"16","author":"Saharinen","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"R8-20251021","doi-asserted-by":"crossref","first-page":"a006550","DOI":"10.1101\/cshperspect.a006650","article-title":"The complex role of angiopoietin-2 in the angiopoietin-tie signaling pathway","volume":"2","author":"Thurston","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"R9-20251021","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","article-title":"Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data","volume":"35","author":"Joussen","year":"2021","journal-title":"Eye (Lond)"},{"key":"R10-20251021","doi-asserted-by":"crossref","first-page":"8219","DOI":"10.1073\/pnas.122109599","article-title":"Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF)","volume":"99","author":"Visconti","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R11-20251021","doi-asserted-by":"crossref","first-page":"100111","DOI":"10.1016\/j.xops.2021.100111","article-title":"YOSEMITE and RHINE: phase 3 randomized clinical trials of faricimab for diabetic macular edema: study design and rationale","volume":"2","author":"Eter","year":"2022","journal-title":"Ophthalmol Sci"},{"key":"R12-20251021","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet"},{"key":"R13-20251021","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","article-title":"Faricimab treat-and-extend for diabetic macular edema: two-year results from the randomized phase 3 YOSEMITE and RHINE trials","volume":"131","author":"Wong","year":"2024","journal-title":"Ophthalmology"},{"key":"R14-20251021","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/IAE.0000000000002024","article-title":"Five-year incidence and risk factors for idiopathic epiretinal membranes","volume":"39","author":"Bae","year":"2019","journal-title":"Retina"},{"key":"R15-20251021","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0161-6420(02)01443-4","article-title":"Five-year cumulative incidence and progression of epiretinal membranes: the Blue Mountains Eye Study","volume":"110","author":"Fraser-Bell","year":"2003","journal-title":"Ophthalmology"},{"key":"R16-20251021","doi-asserted-by":"crossref","first-page":"1192464","DOI":"10.3389\/fncel.2023.1192464","article-title":"Delineating effects of angiopoietin-2 inhibition on vascular permeability and inflammation in models of retinal neovascularization and ischemia\/reperfusion","volume":"17","author":"Canonica","year":"2023","journal-title":"Front Cell Neurosci"},{"key":"R17-20251021","doi-asserted-by":"crossref","first-page":"e0294745","DOI":"10.1371\/journal.pone.0294745","article-title":"Involvement of angiopoietin 2 and vascular endothelial growth factor in uveitis","volume":"18","author":"Suzuki","year":"2023","journal-title":"PLoS One"},{"key":"R18-20251021","first-page":"2816","article-title":"Faricimab reduces macular leakage vs aflibercept in patients with DME","volume":"64","author":"Goldberg","year":"2023","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"R19-20251021","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1097\/IAE.0000000000003223","article-title":"Microvascular leakage is a poor prognostic factor for idiopathic epiretinal membrane: a Fluorescein Angiography Study","volume":"41","author":"Kwon","year":"2021","journal-title":"Retina"},{"key":"R20-20251021","doi-asserted-by":"crossref","first-page":"100972","DOI":"10.1016\/j.preteyeres.2021.100972","article-title":"AI-based monitoring of retinal fluid in disease activity and under therapy","volume":"86","author":"Schmidt-Erfurth","year":"2022","journal-title":"Prog Retin Eye Res"},{"key":"R21-20251021","first-page":"2185","article-title":"Faricimab rapidly improves fluid parameters in patients with nAMD","volume":"64","author":"Querques","year":"2023","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"R22-20251021","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41433-023-02637-2","article-title":"Exploring the role of retinal fluid as a biomarker for the management of diabetic macular oedema","volume":"38","author":"Khoramnia","year":"2024","journal-title":"Eye (Lond)"},{"key":"R23-20251021","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.2147\/OPTH.S146019","article-title":"Vitreoretinal interface abnormalities in diabetic macular edema and effectiveness of anti-VEGF therapy: an optical coherence tomography study","volume":"11","author":"Kulikov","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"R24-20251021","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1167\/iovs.19-26788","article-title":"In vitro epiretinal membrane model and antibody permeability: relationship with anti-VEGF resistance in diabetic macular edema","volume":"60","author":"Namba","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004572","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T19:00:46Z","timestamp":1761073246000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004572","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}